CRISPR technology has been successfully applied to implement the editing and modulation of numerous oncogenes such as epidermal growth factor receptor (EGFR), KRAS, focal adhesion kinase (FAK), metabotropic glutamate receptor 8 (GRM8), SMAD3/4, and MET in lung cancer (Table 1). This evidence concerns the gene KRAS and lung carcinoma.